Kamu erişimi zorunlu olan makaleler - Nikoletta FotakiDaha fazla bilgi edinin
Bir yerde sunuluyor: 29
Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network
Z Vinarov, B Abrahamsson, P Artursson, H Batchelor, P Berben, ...
Advanced drug delivery reviews 171, 289-331, 2021
Zorunlu olanlar: European Commission
Impact of gastrointestinal disease states on oral drug absorption–implications for formulation design–a PEARRL review
A Effinger, CM O'Driscoll, M McAllister, N Fotaki
Journal of Pharmacy and Pharmacology 71 (4), 674-698, 2019
Zorunlu olanlar: European Commission
Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic …
I Loisios-Konstantinidis, R Cristofoletti, N Fotaki, DB Turner, J Dressman
European Journal of Pharmaceutical Sciences 143, 105170, 2020
Zorunlu olanlar: European Commission
Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation
A Taverner, R Dondi, K Almansour, F Laurent, SE Owens, IM Eggleston, ...
Journal of Controlled Release 210, 189-197, 2015
Zorunlu olanlar: UK Medical Research Council, Wellcome Trust
Assessment of age-related changes in pediatric gastrointestinal solubility
AR Maharaj, AN Edginton, N Fotaki
Pharmaceutical research 33, 52-71, 2016
Zorunlu olanlar: Natural Sciences and Engineering Research Council of Canada
BU08073 a buprenorphine analogue with partial agonist activity at μ‐receptors in vitro but long‐lasting opioid antagonist activity in vivo in mice
TV Khroyan, J Wu, WE Polgar, G Cami‐Kobeci, N Fotaki, SM Husbands, ...
British journal of pharmacology 172 (2), 668-680, 2015
Zorunlu olanlar: US National Institutes of Health
Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products–a PEARRL review
M Guimarães, M Statelova, R Holm, C Reppas, M Symilllides, M Vertzoni, ...
Journal of Pharmacy and Pharmacology 71 (4), 603-642, 2019
Zorunlu olanlar: European Commission
Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies
E Grignard, R Taylor, M McAllister, K Box, N Fotaki
European Journal of Pharmaceutical Sciences 99, 193-201, 2017
Zorunlu olanlar: UK Research & Innovation
In vitro and in silico ADME prediction
A Effinger, CM O’Driscoll, M McAllister, N Fotaki
ADME Processes in Pharmaceutical Sciences: Dosage, Design, and …, 2018
Zorunlu olanlar: European Commission
Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling
A Effinger, CM O'Driscoll, M McAllister, N Fotaki
European Journal of Pharmaceutical Sciences 157, 105617, 2021
Zorunlu olanlar: European Commission
Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review
I Loisios-Konstantinidis, RLM Paraiso, N Fotaki, M McAllister, ...
Journal of Pharmacy and Pharmacology 71 (4), 699-723, 2019
Zorunlu olanlar: European Commission
Successful extrapolation of paracetamol exposure from adults to infants after oral administration of a pediatric aqueous suspension is highly dependent on the study dosing …
M Statelova, R Holm, N Fotaki, C Reppas, M Vertzoni
The AAPS Journal 22, 1-17, 2020
Zorunlu olanlar: European Commission
Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review
C Litou, A Effinger, ES Kostewicz, KJ Box, N Fotaki, JB Dressman
Journal of Pharmacy and Pharmacology 71 (4), 643-673, 2019
Zorunlu olanlar: European Commission
The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets
RLM Paraiso, RH Rose, N Fotaki, M McAllister, JB Dressman
European journal of pharmaceutical sciences 155, 105534, 2020
Zorunlu olanlar: European Commission
Gastrointestinal diseases and their impact on drug solubility: Crohn's disease
A Effinger, CM O'Driscoll, M McAllister, N Fotaki
European Journal of Pharmaceutical Sciences 152, 105459, 2020
Zorunlu olanlar: European Commission
On the design of food effect studies in adults for extrapolating oral drug absorption data to infants: an exploratory study highlighting the importance of infant food
M Statelova, K Goumas, N Fotaki, R Holm, M Symillides, C Reppas, ...
The AAPS Journal 22, 1-11, 2020
Zorunlu olanlar: European Commission
Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum
LM Monteiro, R Löbenberg, EJ Barbosa, GLB de Araujo, PK Sato, ...
European Journal of Pharmaceutical Sciences 169, 106097, 2022
Zorunlu olanlar: Fundação de Amparo à Pesquisa do Estado de São Paulo
In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance
Y Tsume, S Patel, N Fotaki, C Bergstrӧm, GL Amidon, JG Brasseur, ...
The AAPS journal 20, 1-8, 2018
Zorunlu olanlar: US National Institutes of Health
Investigating the impact of Crohn’s Disease on the bioaccessibility of a lipid-based formulation with an in vitro dynamic gastrointestinal model
A Effinger, M McAllister, I Tomaszewska, CM O’Driscoll, M Taylor, ...
Molecular Pharmaceutics 18 (4), 1530-1543, 2021
Zorunlu olanlar: European Commission
Factors affecting successful extrapolation of ibuprofen exposure from adults to pediatric populations after oral administration of a pediatric aqueous suspension
M Statelova, R Holm, N Fotaki, C Reppas, M Vertzoni
The AAPS Journal 22, 1-17, 2020
Zorunlu olanlar: European Commission
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir